HUTCHMED (NASDAQ:HCM) Hits New 1-Year Low – Here’s What Happened

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) reached a new 52-week low on Tuesday . The company traded as low as $10.63 and last traded at $10.7790, with a volume of 7730 shares changing hands. The stock had previously closed at $10.85.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HCM. Weiss Ratings downgraded HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 1st. Morgan Stanley set a $13.60 price objective on shares of HUTCHMED in a research report on Thursday, May 28th. Bank of America lowered their price target on HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, March 10th. Finally, Wall Street Zen cut HUTCHMED from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $16.80.

HUTCHMED Trading Down 2.2%

The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average of $13.41 and a 200 day moving average of $14.03.

Institutional Investors Weigh In On HUTCHMED

Institutional investors and hedge funds have recently bought and sold shares of the business. XY Capital Ltd raised its holdings in HUTCHMED by 291.1% during the third quarter. XY Capital Ltd now owns 52,757 shares of the company’s stock valued at $831,000 after acquiring an additional 39,266 shares during the period. Dimensional Fund Advisors LP raised its holdings in HUTCHMED by 157.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock valued at $746,000 after acquiring an additional 34,248 shares during the period. Bank of America Corp DE raised its holdings in HUTCHMED by 5.9% during the third quarter. Bank of America Corp DE now owns 21,791 shares of the company’s stock valued at $343,000 after acquiring an additional 1,209 shares during the period. BNP Paribas Financial Markets grew its position in shares of HUTCHMED by 19.7% during the second quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock valued at $377,000 after purchasing an additional 4,116 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its position in shares of HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after purchasing an additional 698 shares in the last quarter. 8.82% of the stock is owned by institutional investors.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.